Thorlef Spickschen Sells 4,500 Shares of Clovis Oncology, Inc. (CLVS) Stock
Clovis Oncology, Inc. (NASDAQ:CLVS) Director Thorlef Spickschen sold 4,500 shares of Clovis Oncology stock in a transaction dated Friday, December 8th. The shares were sold at an average price of $60.00, for a total value of $270,000.00. Following the completion of the sale, the director now owns 25,618 shares of the company’s stock, valued at $1,537,080. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Clovis Oncology, Inc. (NASDAQ:CLVS) opened at $62.15 on Friday. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.19 and a quick ratio of 3.16. Clovis Oncology, Inc. has a fifty-two week low of $35.38 and a fifty-two week high of $99.45.
Clovis Oncology (NASDAQ:CLVS) last posted its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($1.24) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.18) by ($0.06). Clovis Oncology had a negative net margin of 947.47% and a negative return on equity of 122.06%. The company had revenue of $16.81 million for the quarter, compared to analyst estimates of $21.12 million. During the same quarter last year, the company earned ($1.70) EPS. equities analysts expect that Clovis Oncology, Inc. will post -7.63 EPS for the current fiscal year.
Several analysts recently weighed in on CLVS shares. Evercore ISI started coverage on Clovis Oncology in a report on Wednesday, August 16th. They issued an “in-line” rating and a $73.00 price objective for the company. Leerink Swann reduced their target price on shares of Clovis Oncology to $107.00 and set an “outperform” rating for the company in a report on Friday, August 18th. J P Morgan Chase & Co reiterated a “buy” rating on shares of Clovis Oncology in a report on Friday, August 18th. Cann reiterated a “hold” rating on shares of Clovis Oncology in a report on Monday, September 11th. Finally, Oppenheimer reiterated a “hold” rating on shares of Clovis Oncology in a report on Monday, September 11th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and thirteen have assigned a buy rating to the company. The company has an average rating of “Buy” and an average price target of $86.15.
ILLEGAL ACTIVITY WARNING: “Thorlef Spickschen Sells 4,500 Shares of Clovis Oncology, Inc. (CLVS) Stock” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://www.thecerbatgem.com/2017/12/10/thorlef-spickschen-sells-4500-shares-of-clovis-oncology-inc-clvs-stock.html.
About Clovis Oncology
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
Receive News & Stock Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related stocks with our FREE daily email newsletter.